BATON ROUGE, La., Aug. 17, 2017 -- Amedisys, Inc. (NASDAQ:AMED), one of the nation’s leading home healthcare, hospice, and personal care companies, today announces that their clinical programs team has completed the National Readmission Prevention Collaborative (NRPC) certification program. The certification program provides deeper training and examination on how to appropriately address readmission issues in local communities.
The certification was completed by the Amedisys clinical programs team responsible for the development and delivery of clinically distinct home healthcare programs, including Amedisys’ two newest programs aimed at chronic disease management for Congestive Heart Failure and Chronic Obstructive Pulmonary Disease (COPD) – two conditions responsible for the majority of hospital readmissions. Amedisys is one of the first home care organizations to receive this prestigious honor held in high regard by leading acute hospitals that are being penalized if patients are readmitted unnecessarily to the hospital.
“The Amedisys clinical programs team is proud to become certified by NRPC. Our patients, wherever they may live, deserve the best care possible to avoid unnecessary hospitalizations,” said Amedisys Vice President of Clinical Programs and Innovation Shannon Abbott.
“As an organization, we are committed to empowering our patients, caregivers, clinicians and provider partners through clinically-distinct programs focused on our most frail population to improve outcomes and quality of life,” stated Amedisys Chief Clinical Officer Susan Sender.
Amedisys’ commitment to clinical quality can be seen in its Quality of Patient Care Star rating of 4.13, 3.25% above the national average, as reported by the Centers for Medicare & Medicaid Services (CMS).
“The NRPC certification is quite an accomplishment for the Amedisys clinical team, as it requires extensive knowledge of the healthcare sector as directed in the Affordable Care Act,” said Josh Luke, Founder, and President of the National Readmission Prevention Collaborative.
The certification process includes research, article reviews, a project submission, and exam. More information on the certification can be found at www.NationalReadmissionPrevention.com.
For more information on how Amedisys can help you or your loved one, click here.
About Amedisys
Amedisys, Inc. is a leading healthcare at home Company delivering personalized home health, hospice and personal care. Amedisys is focused on delivering the care that is best for our patients, whether that is home-based personal care; recovery and rehabilitation after an operation or injury; care focused on empowering them to manage a chronic disease; or hospice care at the end of life. More than 2,200 hospitals and 61,900 physicians nationwide have chosen Amedisys as a partner in post-acute care. Founded in 1982, headquartered in Baton Rouge, LA with an executive office in Nashville, TN, Amedisys is a publicly held company. With approximately 16,000 employees, in 421 care centers in 34 states, Amedisys is dedicated to delivering the highest quality of care to the doorsteps of more than 385,000 patients in need every year. For more information about the Company, please visit www.amedisys.com.
Contact: Kendra Kimmons Vice President of Marketing & Communications 225-299-3708 [email protected]


Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings
Anthropic Eyes $350 Billion Valuation as AI Funding and Share Sale Accelerate
Nintendo Shares Slide After Earnings Miss Raises Switch 2 Margin Concerns
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
Australian Scandium Project Backed by Richard Friedland Poised to Support U.S. Critical Minerals Stockpile
Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies
Ford and Geely Explore Strategic Manufacturing Partnership in Europe
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 



